Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AWP549 data for meeting with Daniel

ABSTRACT: Data from Kushneria konosiri for meeting with Daniel 5/20.

INSTRUMENT(S): Xevo G2 Q-Tof, Orbitrap Exploris 120

ORGANISM(S): Kushneria Konosiri (ncbitaxon:698828)

SUBMITTER: Aaron Puri

PROVIDER: MSV000094807 | MassIVE | Mon May 20 10:56:00 BST 2024

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

GNPS - AWP549 data for meeting with Daniel

Project description:Data from Kushneria konosiri for meeting with Daniel 5/20.

2024-05-20 | MSV000094807 | GNPS

I-SPY2-990 mRNA/RPPA Data Resource: RPPA component

Project description:The RPPA component of the I-SPY2-990 mRNA/RPPA Data Resource contains protein/phosphoprotein data from pre-treatment laser capture microdissected (LCM) tumor biopsies for 139 key signaling proteins/phosphoproteins in cancer for 736 patients from 8 arms of the neoadjuvant I-SPY2 TRIAL (NCT01042379) for aggressive early stage breast cancer [194 Control (Ctr); 63 veliparib/carboplatin (VC); 105 neratinib (N); 87 MK2206; 128 trebananib; 49 TDM1/pertuzumab(P); 43 H/P; and 67 pembrolizumab (pembro)]. This record also contains clinical data for these patients, including HR, HER2 and MP status, response (pCR or no pCR), and treatment arm. RPPA endpoints assayed are from hormone receptor (n=4), HER family (n=14), cell cycle/proliferation (n=20), immune (n=18), DNA repair deficiency (DDR; n=15), AKT/mTOR/PI3K (n=7), apoptosis/autophagy (n=10), IGF1R (n=6), TIE/ANG (n=4), growth/survival/metabolism (n=22) and RTK (n=19) pathways. For gene expresson data for all 736 patients with RPPA data, plus an additional 150 patients for a total 987 patients from 10 arms of I-SPY2 (mRNA component of the I-SPY2-990 Data Resource), see the companion GEO record/subseries GSE194040.

2022-05-25 | GSE196093 | GEO

I-SPY2 TRIAL RPPA data for ganitumab arm (and control arm)

Project description:Pre-treatment specimens from patients treated on the I-SPY2 neoadjuvant breast cancer trial were studied to identify predictive biomarkers associated with response to the regimen of paclitaxel, an anti-type I IGF receptor (IGF-1R) antibody ganitumab, and metformin (PGM) followed by doxorubicin and cyclophosphamide (AC) compared to control therapy (paclitaxel followed by AC). This record contains protein/phosphoprotein data from pre-treatment laser capture microdissected (LCM) tumor biopsies for up to 162 key signaling proteins/phosphoproteins in cancer for 221 HER2-negative patients from 2 arms of the neoadjuvant I-SPY2 TRIAL (NCT01042379) for aggressive early stage breast cancer [119 Control; 102 Ganitumab]. This record also contains clinical data for these patients, including HR, and HER2 status, response (pCR or no pCR), and treatment arm. RPPA endpoints assayed are from hormone receptor (n=4), HER family (n=14), cell cycle/proliferation (n=20), immune (n=18), DNA repair deficiency (DDR; n=15), AKT/mTOR/PI3K (n=7), apoptosis/autophagy (n=10), IGF1R (n=6), TIE/ANG (n=4), growth/survival/metabolism (n=22) and RTK (n=19) and other pathways. For gene expresson data for these patients, see the GEO record/subseries GSE194040.

2025-07-30 | GSE298828 | GEO

Antibody microarrays of plasma from bone marrow transplant patients to find markers of graft versus host disease

Project description:A non-invasive diagnostic test does not exist for acute graft versus host disease (aGVHD). We therefore sought to identify biomarkers for aGVHD using antibody microarrays (Schleicher and Schuell Serum Biomarker Chips, Whatman) that simultaneously assayed 120 plasma proteins. We measured these proteins in a set of 42 patient plasma samples following an allogeneic bone marrow transplant (BMT): 21 patients with a diagnosis of aGVHD grade II-IV (+GVHD) and 21 patients without aGVHD (–GVHD) at similar times after transplant. We excluded data from 2 hybridizations that had very bright dots and appeared as outliers in preliminary principal components analysis, so that we finally compared 20 +GVHD to 20 -GVHD samples. Keywords: disease state analysis, antibody microarray

2008-10-31 | GSE9791 | GEO

CARDIA Multi-omics Obesity & CVD Substudy – Year 20 Untargeted Metabolomics Data

Project description:CARDIA Multi-omics Obesity & CVD Substudy – Year 20 Untargeted Metabolomics Data

| PRJNA1122871 | ENA

CARDIA Multi-omics Obesity & CVD Substudy – Year 20 Untargeted Metabolomics Data

Project description:CARDIA Multi-omics Obesity & CVD Substudy – Year 20 Untargeted Metabolomics Data

| PRJNA1122872 | ENA

Proteomic and phosphoproteomic data

Project description:Proteomic and phosphoproteomic data

2020-01-08 | OEX00002200 | NODE

Data-independent acquisition (DIA) mass spectrometry for Moyamoya disease

Project description:This program used data-independent acquisition mass spectrometry to detect the proteins in 80 samples of serum, including 20 health controls, 20 children moyamoya disease (MMD) patients, 20 haemorrhagic MMD patients and 20 Ischemic MMD patients.

2022-12-01 | PXD038468 |

Data

Project description:Data

| PRJNA732383 | ENA

Mucociliary epidermis RNA-seq data from controls during early patterning (st. 14-20)

Project description:Mucociliary epidermis RNA-seq data from controls during early patterning (st. 14-20)

| PRJNA1094966 | ENA